Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?
Vignesh Narasimhan, Francis Cheung, Peadar Waters, Oliver Peacock, Satish Warrier, Craig Lynch, Michael Michael, Robert Ramsay, Alexander Heriot
The Surgeon | ROYAL COLLEGE SURGEONS EDINBURGH | Published : 2020
BACKGROUND AND OBJECTIVES: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers selected patients with peritoneal surface malignancies (PSM) an improved survival. However, a substantial proportion of patients develop peritoneal recurrence. There is limited data on the efficacy of iterative CRS and HIPEC in such patients. This study evaluates the safety, efficacy and outcomes after re-do CRS and HIPEC for PSM at a tertiary institute. METHODS: Patients undergoing re-do CRS and HIPEC for recurrent PSM were included. Cases were grouped into the first and iterative cases and compared to evaluate differences in morbidity, survival and factors influencing surviv..View full abstract